(Q37845643)

24 August 2017

1 reference

title

Renal failure in multiple myeloma: a medical emergency (English)

1 reference

24 August 2017

1 reference

B Wirk

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

21 February 2011

1 reference

Bone Marrow Transplantation

24 August 2017

published in

1 reference

24 August 2017

volume

46

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

771-783

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2011.8

24 August 2017

exact match

0 references

cites work

Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Renal insufficiency and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Multiple Myeloma with Massive Bence Jones Proteinuria and Preservation of Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Nephrotoxic potential of Bence Jones proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Renal, hematologic and infectious complications in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Long-term outcome of autologous stem cell transplantation in light chain deposition disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Light-chain (AL) amyloidosis: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

High dose chemotherapy in light chain or light and heavy chain deposition disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Azotemia associated with use of lenalidomide in plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Renal Failure in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

https://api.crossref.org/works/10.1038%2FBMT.2011.8

1 reference

7 January 2021

Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Light chains are a ligand for megalin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Glomerular and proximal tubular morphology after single nephron obstruction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Long-term outcome of renal transplantation in light-chain deposition disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.8

7 January 2021

Identifiers

DOI

10.1038/BMT.2011.8

1 reference

24 August 2017

1 reference